Tetraphase hires Patheon to make its synthetic antibiotic eravacycline

By Gareth Macdonald contact

- Last updated on GMT

Source Google maps
Source Google maps

Related tags: Active pharmaceutical ingredient, U.s. securities and exchange commission, Contract

Tetraphase Pharmaceutical has hired Patheon UK Limited to make and test the synthetic antibiotic eravacycline.

The deal – details of which were set out in a US Securities and Exchange Commission (SEC) filing​ – will see Patheon turn the active pharmaceutical ingredient (API) into the dosage form at its facility in the UK.

The contractor – which is part of Netherlands-headquartered contractor Patheon NV - will also conduct quality control, quality assurance, analytical testing and stability testing and packaging.

Tetraphase also said it expects to sign two further agreements with Patheon covering the manufacture of eravacycline at its sites in Greenville, North Carolina and Ferentino, Italy.

More contracts 

The Massachusetts-based developer will manufacture the active pharmaceutical ingredient (API) and supply it to the three Patheon sites.

Tetraphase has “agreed to order from Patheon at least a certain percentage of its annual commercial requirements for eravacycline in the United States and European Union each year for the term of the Master Agreement​.”

The agreement ends in December 2022, however, it will renew automatically for four two year terms.

The manufacturing contract is the first made public by Patheon since Thermo Fisher Scientific announced its intention to acquire the contractor in May​. 

Synthetic antibiotic

Eravacycline, Tetraphase’s lead candidate, is designed to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria.

The US Food and Drug Administration (FDA) has assigned the drug Qualified Infectious Disease Product​ (QIDP) and Fast Track status. It is currently being examined in a Phase III​ trial.

Eravacycline, like others in Tetraphase's pipeline, was developed using synthesis know how detailed in a paper​ published by researchers at Harvard Univerity in 2005.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us


View more